LEN-TACE sequential therapy tops LEN monotherapy in unresectable HCC responsive to initial LEN treatmentMarch 21, 2022Hepatocellular Carcinoma
Final phase 2 results testify to the clinical advantage of TACE plus sorafenib in unresectable HCCMarch 21, 2022Hepatocellular Carcinoma
Overall survival after curative resection for HBV-related HCC is better with tenofovir vs. entecavirMarch 21, 2022Hepatocellular Carcinoma
Old age and liver stiffness on transient elastography may predict HCC occurrence after HCV eradicationFebruary 22, 2022Hepatocellular Carcinoma
Liver resection in HCC: Robot-assisted and laparoscopic vs. openFebruary 22, 2022Hepatocellular Carcinoma
Tenofovir disoproxil fumarate vs. entecavir: Curtailing the risk of chronic hepatitis B-induced HCCFebruary 22, 2022Hepatocellular Carcinoma
Sorafenib plus HAIC a favorable therapeutic option for HCC with major portal vein tumor thrombosisFebruary 22, 2022Hepatocellular Carcinoma
Posthepatectomy antiviral therapy boosts survival outcomes in HBV-related HCCFebruary 22, 2022Hepatocellular Carcinoma
H1-antihistamines may ward off HCC from patients with HBV, HCV, or dual infectionsFebruary 22, 2022Hepatocellular Carcinoma
Lenvatinib proves its worth against HCC in the real-world settingFebruary 22, 2022Hepatocellular Carcinoma
GALAD performs modestly in detecting HCC in a phase 3 biomarker studyFebruary 22, 2022Hepatocellular Carcinoma
Resectable HCC: Neoadjuvant cemiplimab appears effective and safe in phase 2February 22, 2022Hepatocellular Carcinoma
Phase 2 validates the safety and efficacy of nivolumab with or without ipilimumab in resectable HCCFebruary 22, 2022Hepatocellular Carcinoma
